Bicyclic cyclohexose nucleic acid analogs

a technology of cyclohexose and bicyclic nucleic acids, applied in the field of new products, can solve problems such as loss of the normal function of the target rna

Inactive Publication Date: 2015-07-09
IONIS PHARMA INC
View PDF1 Cites 166 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes novel bicyclic nucleoside analogs and oligomeric compounds prepared therefrom. These analogs have a core structure comprising a cyclohexyl ring wherein one of the ring carbons is replaced with a heteroatom. The analogs can hybridize to a portion of a target RNA, resulting in loss of normal function. The oligomeric compounds can be used as primers and probes in diagnostic applications. The patent also describes the various substituents that can be added to the analogs, such as halogen, OJ5, N(J5)(J6), and more. Overall, the patent provides new tools for research and development of new molecules with potential therapeutic applications.

Problems solved by technology

In certain embodiments, the oligomeric compounds are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bicyclic cyclohexose nucleic acid analogs
  • Bicyclic cyclohexose nucleic acid analogs
  • Bicyclic cyclohexose nucleic acid analogs

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of (1R,3R,4R,7S)-7-(2-cyanoethoxy(diisopropylamino)phosphin oxy)-1-(4,4′-dimethoxytrityloxymethyl)-3-(N-Bz-(Cytidin-1-yl)-2,5-dioxa-bicyclo[2.2.2]octane (14 U, 16 C)

[0268]

[0269]Note: Compound 4 was prepared from compound 1 by a slightly modified version of the procedures found in Tetrahedron Lett., 1993, 1653 and Tetrahedron, 2004, 6813.

Compound 1

[0270]The starting material, Compound 1, is prepared according to the procedure of Moffatt et al, J. Org. Chem., 1979, 44, 1301. Compound 1 is also commercially available from a number of vendors.

Compound 2

Alkylation of Diacetone Glucose

[0271]NaH (60% in Mineral oil, 49.2 g, 1.6 equivalents) was added to a 2 L round bottom flask flushed with nitrogen, and the NaH was washed with hexanes (2×1.0 L) to remove the mineral oil. After decanting the hexanes, DMF (700 mL) was added and the mixture was cooled in an ice bath. Diacetone glucose (1, 200 g, 0.77 moles) was then added over a period of 30 minutes. The ice-bath was removed and ...

example 2

Preparation of (1S,3R,4S,7R)-7-(2-cyanoethoxy(diisopropylamino)phosphin oxy)-1-(4,4′-dimethoxytrityloxymethyl)-3-(heterocyclic base radical)-2,5-dioxa-bicyclo[2.2.2]octane (27)

Route 1:

[0288]

Route 2: Alternative Procedures to Prepare Compound 20

[0289]

[0290]Compound 6 is prepared as per the procedures illustrated in Example 1.

example 3

Preparation of (1R,3R,4R,8R)-8-(2-cyanoethoxy(diisopropylamino)phosphin oxy)-1-(4,4′-dimethoxytrityloxymethyl)-3-(heterocyclic base radical)-2,5-dioxa-bicyclo[2.2.2]octane (39)

[0291]

[0292]Compound 6 is prepared as per the procedures illustrated in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.

Description

FIELD OF THE INVENTION[0001]Provided herein are novel bicyclic nucleoside analogs and oligomeric compounds and compositions prepared therefrom. More particularly, bicyclic nucleoside analogs are provided wherein the naturally occurring pentofuranose ring is replaced with a cyclohexyl ring that comprises one ring heteroatom and a bridge making the ring system bicyclic. In certain embodiments, the oligomeric compounds and compositions of the present invention are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The oligomeric compounds provided herein are also expected to be useful as primers and probes in diagnostic applications.SEQUENCE LISTING[0002]The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled CHEM0030USC1SEQ_ST25.txt, created on Mar. 18, 2015 which is 8 Kb in size. The information in the electronic format of the sequence listing...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/113C07H19/06
CPCC07H19/06C12N15/113C07H19/16C07H21/00
Inventor MIGAWA, MICHAEL T.SETH, PUNIT P.SWAYZE, ERIC E.ROSS, BRUCE S.SONG, QUANLAIHAN, MINGMING
Owner IONIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap